taxane
1 product
42 abstracts
Abstract
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.Org: Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Gangnam Severance Hospital, Seoul St. Mary's Hospital,
Abstract
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).Org: Kanagawa Cancer Center, Fukushima Medical University, School of Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), National Cancer Center Hospital East, Kashiwa, Japan, Department of Breast Surgery, Shizuoka General Hospital,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
Dynamic androgen receptor alterations (ARa) ctDNA profiles and clinical outcomes in metastatic prostate cancer (mPC).Org: University of San Diego,
Abstract
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Pathology, SUNY Upstate Medical University,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study.Org: Jiaotong University,
Abstract
Triage of advanced cervical cancer through immunotherapy induction (TRACTION).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).Org: Hospital of Xinjiang Production and Construction Corps,
Abstract
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium.Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ,
Abstract
Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer.Org: University of Illinois Hospital & Health Sciences System, University of Illinois Chicago, Stanford University School of Medicine,
Abstract
A phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and preliminary efficacy of SCB-219M in patients with chemotherapy-induced thrombocytopenia (CIT): An interim analysis.Org: Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Sixth People's Hospital of Chengdu,
Abstract
Improving chemotherapy-induced alopecia for women receiving anthracycline plus taxane chemotherapy using the Paxman scalp cooling system at lower temperatures.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Dermatology Service, NYU Langone Health, New York, NY,
Abstract
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.Org: Centre Léon Bérard, Centre Paul Papin, Lorraine Cancer Institute, Hôpital Européen Georges Pompidou, CHU Hautepierre,
Abstract
Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first‑line (1L) treatment stratified by BRCA status.Org: Janssen, Janssen Pharmaceuticals, Janssen Research & Development, Janssen-Cilag B.V., Janssen Pharmaceutica NV,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer.Org: Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Queen Elizabeth Hospital, Hong Kong Sanatorium & Hospital,
Abstract
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.Org: Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,
Abstract
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).Org: University of Pennsylvania, Stanford Cancer Center,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.Org: Southwest Hospital Army Medical University, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China,
Abstract
Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.Org: Southwest Hospital Army Medical University, Army Medical University, Chongqing Precision Biotech, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China, 29 Gaotanyan Main Street,
Abstract
Patterns of ovarian cancer care in an elderly population in Australia: A prospective cohort study from the National Gynaecology Oncology Registry (NGOR).Org: Monash University School of Public Health and Preventive Medicine, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Women's Hospital, Epworth Healthcare,
Abstract
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.Org: Department of Medicine, Duke University School of Medicine, Texas Oncology-Baylor Charles A. Sammons Cancer Center, PIH Health Whittier Hospital, Nebraska Hematology-Oncology P.C., Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles/Jonsson Comprehensive Cancer Center,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,
Abstract
Therapeutic strategies for metaplastic breast cancer: A clinicopathologic analysis of a single institution cohort.Org: University of California San Diego Medical Center, La Jolla, CA, UC San Diego Moores Cancer Center,
Abstract
Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patients.Org: Medanta Medicity, Medanta - The Medicity, Medanta- The Medicity, Medanta-The Medicity, Medanta The Medicity,
Abstract
Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancer.Org: Memorial Sloan Kettering Cancer Center, Renaissance School of Medicine at Stony Brook University, School of Health Science, Stockton University,
Abstract
Characterization of patients with recurrent breast cancer submitted to neoadjuvant therapy in a Brazilian cancer center.Org: A.C. Camargo Cancer Center, Hospital ACCamargo, A.C. Camargo Hospital,
Abstract
Early taxane-induced neurotoxicity and quality of life in patients with breast cancer: A single center, retrospective study.Org: Medical Oncolgy Unit, University Hospital and University of Cagliari, University Hospital of Cagliari,
Abstract
Efficacy comparison of anthracycline and taxane when added to immune checkpoint inhibitor in neoadjuvant chemotherapy of triple negative breast cancer: Clinical evidence from size-reduction measurement by ultrasound.Org: Chang Gung Memorial Hospital at Taipei, Chang Gung University Medical College, Chang Gung Memorial Hospital, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Practice patterns in ongoing neoadjuvant ATNEC trial for patients with cT1-3N1M0 breast cancer: Response to neoadjuvant chemotherapy (NACT), targeted axillary dissection and breast conservation rates.Org: Royal Derby Hospital, University of Warwick, Royal Cornwall Hospitals NHS Trust, Aberdeen Royal Infirmary, NCRI Breast Clinical Studies Group,
Abstract
Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).Org: Department of Breast Surgery Osaka Medical and Pharma ceutical University, Osaka Medical and Pharmaceutical University, Department of Rehabilitation Medicine Osaka Medical College, Osaka Medical snd Pharmaceutical University, Osaka Police Hospital,
Abstract
Recurrent versus non-recurrent triple negative breast cancer: An institutional study.Org: Geisinger Northeast, Wilkes Barre, PainReform, The Pennsylvania State University, State College,
Abstract
Analysis on real-world chemotherapy outcomes in patients (pts) with tyrosine kinase inhibitor (TKI) resistant advanced EGFR-mutant non–small-cell lung cancer (NSCLC) in the United States.Org: Merck, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Role of plasma circulating HER2/EFTUD2 ratio in predicting pathological complete response (pCR) after neoadjuvant dual anti-HER2 therapy in HER2-positive breast cancer (HER2+ BC).Org: Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong, Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, Hong Kong, Departments of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong, Queen Elizabeth Hospital, Kowloon, Hong Kong, Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong,
Abstract
ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,
Abstract
Costs and health care resource utilization (HCRU) for patients with advanced biliary tract (aBTC) cancer using administrative databases in Ontario, 2010 to 2020.Org: Sunnybrook Research Institute, AstraZeneca Canada, University Health Network,
Abstract
High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.Org: Weill Cornell Medical College University, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, NewYork-Presbyterian/Weill Cornell Medical Center, Joan and Sanford I Weill Medical College of Cornell University, NYP/Columbia,
Abstract
Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status.Org: Gilead Sciences Canada, University of Calgary, Gilead Sciences Europe Ltd.,
Abstract
Male breast cancer survival data and clinicopathological characteristics: A single-centre experience.Org: Hospital Agios Savvas, Agios Savvas Cancer Hospital, Saint Savvas Hospital, Agios Savvas Anticancer Hospital, Second Department of Medical Oncology,